

The Myths and FAQs of Alzheimer's disease

Dr. Timothy Chang, MD, PhD, Neurology Department Samantha Shah, BS

Myth: Dementia and Alzheimer's disease are the same thing



Alzheimer's disease is a type of dementia, accounting for 60–80% of all dementia cases. Other types of dementia include frontotemporal dementia (FTD), vascular dementia, mixed dementia, and Lewy body dementia.

The National Institute on Aging define dementia as "the loss of cognitive functioning — thinking, remembering, and reasoning — and behavioral abilities to such an extent that it interferes with a person's daily life and activities."

Myth: Dementia is inevitable with age

Dementia is not a normal part of aging. Age is a risk factor

According to a report that the Alzheimer's Association published, Alzheimer's disease, which is the most common form of dementia, affects 3-10% of people aged 65–74 years in the U.S.

As a result of the risk increasing as we age, 17% of people aged 75–84 years and 32% of people aged 85 years and older have a dementia diagnosis

Myth: Memory loss always signifies dementia

Although memory loss can be an early symptom of dementia, it does not necessarily signify the start of this condition. Human memory can be unpredictable, and we all forget things occasionally.

However, if memory loss is interfering with everyday life, it may be one symptom of dementia



Myth: Dementia only affects older adults

Age is a risk factor for dementia, but dementia can affect younger adults in rare cases. Some scientists estimate that, in people aged 30–64 years, 38–260 people in 100,000 (0.038%–0.26%) develop early-onset dementia.

In the 55–64 age bracket, this increases to close to 420 people in 100,000 (0.4%).

Myth: A family member has dementia, so I will get it

A common myth is that dementia is purely genetic. In other words, if a person's family member has a dementia diagnosis, they are guaranteed to develop dementia later in life. This is not true.

Although there is a genetic component to some forms of dementia, the majority of cases do not have a strong genetic link.

Early-onset Alzheimer's disease is relatively uncommon. It occurs in about 5.5% of all Alzheimer's disease cases.

Myth: Dementia signals the end of a meaningful life

Thankfully, this is not the case. Many people with a dementia diagnosis lead **active**, **meaningful** lives.



What is the difference between Alzheimer's disease and other types of dementia?

- o AD
- o Vascular dementia

Other characteristics

- Frontotemporal dementia
- Lewy body dementia

Progressive Supranuclear Palsy

Corticobasal Syndrome





What does a typical diagnostic work up look like for AD/Dementia? What test should be included?

History and Physical

TSH, B12

MRI brain



When is a PET scan/MRI/spinal tap needed? Should they push for these?

Not always necessary

Consider if additional symptoms



How fast will disease progress? Is there a way to slow down the progression?

- Independent to needing some help \rightarrow 3-5 years
- Yes, progression may be slowed down

Table 5. Dementia Severity Categories Based on CDR-SB Scores

CDR-SB Range	Staging Category		
0	Normal		
0.5-4.0	Questionable cognitive impairment		
0.5-2.0	Questionable impairment		
2.5-4.0	Very mild dementia		
4.5-9.0	Mild dementia		
9.5-15.5	Moderate dementia		
16.0-18.0	Severe dementia		

Abbreviation: CDR-SB, Clinical Dementia Rating Scale Sum of Boxes score.

While the clinical course as measured by such scales is not necessarily linear, a number of studies have found that patients decline 3 to 3.5 points on average

What medications are available for AD/dementia and what do they actually do?

- Anticholesterase inhibitors donepezil, rivastigmine
 - Increase cholinergic system
- Memantine N-methyl-D-aspartate (NMDA) receptor antagonist.
 - Moderate to severe AD
 - Neuroprotective
- o Aducanumab
 - Block amyloid
- Vascular risk factor, Behavior, Nonpharmacologic



If someone has serious side effects to AD/dementia meds, will they decline faster because they are not taking anything?

Anticholinesterase inhibitors

 Delayed loss of independence for few months

Memantine

- For cognition, function and behavior, there is mild benefit
 - No change (memantine) vs mild worsening (placebo) over 6 months

Mild benefit, so if not taking, not a major decline

Review: Cholinesterase in hibitors for Alzheimer's disease Comparison: 1 Cholinesterase in hibitor (opfimum dose) vs placebo Outcome: 2 MMSE mean change in score trom baseline at 6 months or later (ITT-LOCF)

Study or subgroup	ChEI N	Mean (SD)	Placebo N	Mean (SD)	Mean Difference IV,Fixed,95% Cl
DON-302	150	0.39 (3.1)	154	-0.97 (3.1)	-
DON-311	103	-0.1 (4.05)	102	-0.81 (4.03)	-+-
DON-402	91	1.33 (3.44)	55	0.09 (3.05)	-+
DON-Feldman	131	1.35 (4.01)	139	-0.44 (3.99)	
DON-Nordic	135	-0.5 (4.1)	137	-2.2 (3.3)	
RIV-B303	242	0.22 (3.5)	239	-0.5 (3.6)	
RIV-B304	227	-0.6 (3.6)	220	-1.4 (3.6)	-8-
RIV-B351	354	-0.05 (3)	173	-0.7 (3)	-
RIV-B352	231	2 (3)	235	-0.9 (3)	-
Total (95% CI) Heterogeneity: Chi≥ – 48.53, Test for overall effect: Z – 11.2 Test for subgroup differences:	38 (P < 0.00001	x01); l≏ - 83%)	1454		•
				-10 Favours placebo	-5 0 5 10 Favours ChEl

Do natural supplements help with decreasing progression of disease?

Vitamin E

??? Antioxidants Resveratrol and curcumin Vitamin D Ginkgo Biloba Ginseng Huperzine Vitamins B12 and B9



Are any alternative medications such as psychotropics or medical marijuana recommended to help with anxiety or other symptoms related to dementia?

- Antipsychotics
 - Black box warning in older adult:
 - increased mortality
 - But used to control behavior
- Anxiety
- SSRI sertraline, citalopram
 We typically don't use medical marijuana





Are there any lifestyle/nutrition changes that can help with brain health?

- Reduces vascular risk factors: high cholesterol, hypertension, smoking, diabetes, obesity
- Nutrition
- Exercise
- Cognitive Training
- o Multidisciplinary

	Odds ratio (95% CI)	p value					
	Intervention (n=554)	Control (n=565)					
Overall cognitive decline							
NTB total score	1 (reference)	1.31 (1.01–1.71)	0.04				
Cognitive decline per domain							
NTB memory score	1 (reference)	1.23 (0.95–1.60)	0.12				
NTB executive functioning score	1 (reference)	1.29 (1.02–1.64)	0.04				
NTB processing speed score	1 (reference)	1.35 (1.06–1.71)	0.01				
NTB=neuropsychological test battery							

Table 2 Risk of cognitive decline from baseline to 24 months

For questions regarding your own healthcare, please reach out to your doctor for a more in-depth and personalized consultation

For more information about clinical trials and research at UCLA please contact Monica Moore at mmoore@mednet.ucla.edu

For UCLA clinic information or appointments please call 310-794-1195 or visit <u>https://eastonad.ucla.edu</u>

Thank You